

A commercial-scale viral vector manufacturing facility

Benefits to jobs and industry

The NSW Government has committed to expand and operate a world-leading viral vector manufacturing facility in the Westmead Health and Innovation District in western Sydney. The first of its kind in Australia, the facility will meet the growing demand in Australia and internationally for clinical-grade viral vectors, which are a key component of gene therapies and vaccines.

Benefits for jobs and the economy


Investment in viral vector manufacturing will secure supplies of viral vectors for local use, lead to more jobs and more opportunities for local businesses, diversify local industries, and boost Australia's global position as an advanced manufacturing industry.

Countries in the northern hemisphere, including Canada, the United Kingdom and Germany, are increasing their viral vector manufacturing capacity, while in the Asia-Pacific region there is only a small-scale (15-litre) facility in Singapore. However, there are no Good Manufacturing Practices (GMP) licensed viral vector manufacturers in Australia. A commercial-scale viral vector manufacturing facility will fill this gap, contributing to local and overseas markets, with the potential to increase economic benefits for NSW.

Increased local manufacturing capacity will benefit jobs through the development of new and innovative therapeutics. It will support drug development, enable commercialisation of locally-developed therapies, and retain Australian ownership of intellectual property. Expansion of the viral vector manufacturing facility will attract expertise and jobs to the region, benefit research and innovation in cell and gene therapies, and help save lives and cure diseases to make Australians safer.

“Investing in advanced biomanufacturing puts NSW at the forefront of technology and innovation that will change people’s lives for the better.”

– Stuart Ayres
Minister for Jobs, Investment,
Tourism and Western
Sydney



By attracting and retaining local specialist expertise, the facility will cultivate a skilled and collaborative workforce. Developing the technology to manufacture viral vectors locally will allow Australia to retain high-value intellectual property.

More than half of Australia's medical technology companies are based in NSW. Gene and gene-modified cell therapies are growing faster than any other field of regenerative medicine. Gene therapies are estimated to become a \$12 billion revenue market by 2030. If NSW can capture a 5 per cent share of the regenerative medicine market through strategic investment in gene and gene-modified cell therapies, this would represent billions of dollars in annual revenue for the state and create approximately 6,000 jobs over the next 15 years.

Benefits for an advanced manufacturing industry

The viral vector manufacturing facility will position NSW as a leader in future health research and innovation. It will promote a culture of medical research and modern manufacturing in partnership with industry and help develop an advanced manufacturing industry.

The facility will be a catalyst for investment and innovation in cell and gene therapies, and grow capacity and demand for businesses supporting these new advanced manufacturing industries. This will create a significant new export market for NSW with flow-on benefits for broader economic development and output in related industries.





An advanced manufacturing industry will stimulate significant revenue and create jobs in production and supply, medical research and clinical trials, and other science, engineering, and business areas.

Private industry bodies are interested in co-investing in an advanced manufacturing facility that leverages NSW research expertise and accesses the Asia-Pacific markets. Involving private industry could help leverage manufacturing and commercialisation expertise and cost-share ongoing operational costs.

Partnering with the viral vector manufacturing facility is an exciting opportunity to invest in a growing sector of medical health research, the first advanced manufacturing facility of its kind in Australia.

“By having a viral vector manufacturing facility in NSW, there will be a lot of intellectual property coming directly from manufacturing, with the most significant IP being the therapeutics themselves.”

– Dr Leszek Lisowski
Head of Translational Vectorology
Unit, Children’s Medical
Research Institute



For more information

Phone: (02) 9978 5402

Email: HI-Commercial@health.nsw.gov.au

Web: www.hifra.health.nsw.gov.au/commercial